ogf glutathione ingredients Acetyl-Glutathione 100 mg Liposomal Glutathione - 45 Softgel

Non-G12C mutant inhibitors Non-G12C KRAS mutations, particularly G12D and G12V, are highly prevalent in PDAC and CRC and lack a cysteine residue for covalent targeting, necessitating alternative therapeutic strategies.46 MRTX1133 was the first non-covalent KRAS-G12D inhibitor (G12Di) discovered through structure-based design, binding both GDP-bound and GTP-bound states with ~700-fold selectivity over wild-type KRAS protein.47 In PDAC mouse models, it induced tumour regression and shifted tumours towards a classical phenotype, enhancing chemosensitivity.48 Although MRTX1133 advanced to a phase 1/2 trial (NCT05737706), the study was terminated in 2025 due to variable and suboptimal pharmacokinetics despite an acceptable safety profile

(PubMed) Takaya J, Higashino H, Kobayashi Y

CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4

Rossi, Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis